Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812995 | 1.00 | RXRA (0.46) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL6049129 | 0.86 | RXRA (0.43) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL17319636 | 0.83 | RXRA (0.47) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL172834 | 0.81 | RXRA (0.46) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL169517 | 0.81 | RXRA (0.46) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL24108532 | 0.81 | RXRA (0.46) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL172532 | 0.81 | RXRA (0.46) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL129227 | 0.81 | RXRA (0.49) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL2390020 | 0.81 | RXRA (0.49) | RXRARXRGKIF11L3MBTL1XDH | |
| SCHEMBL3598398 | 0.80 | KIF11 (0.57) | RXRARXRGKIF11TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-09-26 | — | — | US | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4294800-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-116997546-A | APOL1 inhibitors and methods of use | 梅兹治疗公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2022178315-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-105008355-B | Azaindole derivatives as protein kinase inhibitors | 奥里巴斯医药公司 | 2017-08-04 | — | — | CN | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| CN-1938314-A | Tetrahydroquinoline derivatives and process for producing the same | TANABE SEIYAKU CO (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1730152-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095409-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| JP-2005272324-A | 3-FORMYL-5-TRIFLUOROMETHYLBENZONITRILE DERIVATIVE AND ITS MANUFACTURING METHOD | CENTRAL GLASS CO LTD | 2005-10-06 | — | — | JP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | RXRA 2254/4885RXRG 2391/4885KIF11 4651/4885 |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | RXRA 2833/4885RXRG 2501/4885KIF11 2176/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | RXRA 468/4885RXRG 574/4885KIF11 4073/4885 |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, SAAL1, APOB | RXRA 243/4885RXRG 268/4885KIF11 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.